Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and twelve have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $34.6364.

IMNM has been the subject of several analyst reports. Truist Financial lifted their price objective on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Barclays initiated coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target on the stock. Leerink Partners lowered their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th.

Immunome Stock Down 1.2%

Shares of IMNM stock opened at $24.67 on Friday. The stock has a 50-day simple moving average of $25.33 and a 200 day simple moving average of $22.71. The stock has a market capitalization of $2.80 billion, a P/E ratio of -9.75 and a beta of 2.13. Immunome has a fifty-two week low of $8.93 and a fifty-two week high of $30.06.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, sell-side analysts anticipate that Immunome will post -2.38 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Max Rosett sold 60,000 shares of Immunome stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the completion of the transaction, the chief financial officer owned 54,037 shares in the company, valued at approximately $985,094.51. This trade represents a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the sale, the insider owned 50,366 shares of the company’s stock, valued at $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 682,310 shares of company stock valued at $15,675,566 over the last 90 days. 7.21% of the stock is owned by company insiders.

Institutional Trading of Immunome

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Immunome by 44.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock valued at $316,000 after acquiring an additional 14,398 shares during the last quarter. Creative Planning acquired a new position in shares of Immunome during the second quarter valued at about $167,000. Rhumbline Advisers boosted its stake in Immunome by 22.0% during the 2nd quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock valued at $1,008,000 after purchasing an additional 19,526 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Immunome by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock worth $2,612,000 after buying an additional 9,686 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Immunome in the 2nd quarter worth $1,021,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Company Profile

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.